Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto.
The agreement provides Stem Cell Therapeutics ("SCT") with an option to an exclusive world-wide license to an innovative cancer stem cell program.
This agreement produced a license for a UHN technology on April 17, 2013.
Matt Ratto, assistant professor in the University of Toronto's Faculty of Information and co-inventor and CEO of Shotlst, a UTEST company, was featured in the Globe and Mail on October 22 in an article by Nick Rockel on how emerging technology will change the education experience.
Here's an excerpt:
Asked what the technological tools in university classrooms will look and feel like by 2020, Matt Ratto admits he’s no futurist. But the assistant professor at the University of Toronto’s Faculty of Information is ...
TORONTO, ON – A new program that provides nascent software companies with start-up funds, work space, mentoring and business strategy support, was launched today by the University of Toronto and commercialization partner MaRS Innovation, with support from the MaRS Discovery District.
TechVibes has a profile page for UTEST and covered CoursePeer as part of their students start-ups series.
The new program, called University of Toronto Early Stage Technology (UTEST), is part of a growing ecosystem of incubators and commercialization support services at U ...
ScarX Therapeutics, a spin-off company created by MaRS Innovation and The Hospital for Sick Children (SickKids), was profiled by Business Without Borders on September 25, 2012.
Sean Fine's article examines the strategic funding partnership MI pursued with NovoTek Therapeutics Inc. (NovoTek) in China to develop the anti-scarring cream, which was discovered by researchers at SickKids.
A multibillion-dollar market may await ScarX, a Toronto biomedical start-up, but first it had to figure out how to finance the development of its unique cream that reduces scarring ...
Encycle Therapeutics, a MaRS Innovation spin-off company, was included in BioCentury's companies to watch within the macrocycle chemistry space.
The reference came in Chris Cain's article, "Maturing macrocycle chemistry drives explosion of biotech newcos, biopharma deals." (more…)
Professors Joyce Poon and Hossein Rahnama, who each have inventions within MaRS Innovation's portfolio of spin-off companies and licenseable technologies, have been named to the MIT Technology Review's prestigious 35 Inventors Under 35 list for 2012.
Poon, an assistant professor of electrical and computer engineering at the University of Toronto, was recognized for, according to MIT's Technology Review, "creating new optical modulators with microscopic loop-the-loops through which light can shuttle data between servers and even from chip to chip within a single ...
Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury.
Here's an excerpt (the article only available to BioCentury subscribers):
PCR-based diagnosis of infections can delay treatment decisions by days or hours because the method relies on technical expertise and equipment not available in most point-of-care settings. Xagenic Inc.'s chip-based arrays use a non-PCR, electrochemical approach to diagnose bacterial infections at the point of care in 20 minutes with PCR-like accuracy.
Xagenic's core technology is a silicon chip containing ...
The Los Angeles Times featured Dr. Gregory Czarnota's research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).
Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound. (more…)